Associate Clinical Professor of Medicine, USC-Keck School of Medicine
Hematology
Dr. Steven J. O'Day, MD
|
|
Give Review
Steven O'Day practices Hematology. He researched medicine at Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a one of the best medicals schools. Johns Hopkins University School of Medicine is ranked 3/29 in Research/PrimaryCare. He received awards:"CMS Meaningful Use Stage 1 Certification", "Top MD" and "Super Doctor". Steven O'Day is a published doctor. He has 41 publications published. The most current publication "Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma." He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma.
- Survival follow-up and ipilimumab reTreatment for patients with advanced melanoma who received ipilimumab in prior phase II studies.
- Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436).
- Development of ipilimumab: a novel immunotherapeutic approach for the Treatment of advanced melanoma.
- Efficacy and safety of reTreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control.
- Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Pat...
- Sunitinib Therapy for Melanoma Patients with KIT Mutations.
- BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced...
- Systemic treatment of metastatic melanoma: New approaches.
- A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.
- Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma.
- Improved survival with ipilimumab in patients with metastatic melanoma.
- Serial monitoring of circulating tumor Cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma.
- A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
- Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective Analysis of HLA subtype from four trials.
- Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
- A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesoni...
- mRNA expression and BRAF mutation in circulating melanoma Cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclon...
- Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the Treatment of melanoma and other malignancies.
- Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy.
- Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma.
- Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III Malignant melanoma.
- Estrogen receptor-alpha methylation predicts melanoma progression.
- Association of circulating tumor Cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients.
- Microphthalmia transcription factor as a molecular marker for circulating tumor Cell detection in blood of melanoma patients.
- Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
- Serial monitoring of circulating melanoma Cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
- Multimarker quantitative real-time PCR detection of circulating melanoma Cells in peripheral blood: relation to disease stage in melanoma patients.
- Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
- Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts Disease outcome.
- Quantification of circulating DNA in the plasma and serum of Cancer patients.
- Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma.
- Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic Cancer vaccine.
- Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional ...
- Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to ind...
- Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving ...
- Results from a randomized phase III study comparing combined Treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with me...
- Metastatic melanoma: chemotherapy to biochemotherapy.
- Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels.
- Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.
Schools
Johns Hopkins University School Of Medicine
Johns Hopkins Hospital
Dana Farber Cancer Institute
Procedures Preformed
- Biopsy
- Bone Marrow Transplant
- Breast Cancer Treatment
- Cancer Counseling
- View All
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Oncology
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Top MD
- Super Doctor
Education
-
Brigham and Women's Hospital -
Johns Hopkins University -
Johns Hopkins University School of Medicine
Hospital
-
St. John's Regional Medical Center -
Cedars-Sinai Medical Center
Drug Facts
| NPI NUMBER | 1518070812 | |
| NPPES Provider LastName | O'DAY | |
| NPPES Provider FirstName | STEVEN | |
| NPPES Provider ZIPCode | 902111958 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 191.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1518070812 |
| Last Name Of The Provider | O'DAY |
| First Name Of The Provider | STEVEN |
| View All |
Similar Doctors
|
|
Dr. Kevin S. Scher, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sepehr Rokhsar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anjali A. Bharne, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Herman E. Kattlove, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marina Vaysburd, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erwin P. Gabor, MD |
|
|
Dr. Yeenan G. Lin, MD |
|
|
Dr. David P. Wu, MD |